View in EDS PDF Full Text

Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.

Saved in:
Bibliographic Details
Title: Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.
Authors: Subbarayan K; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Massa C; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Leisz S; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Steven A; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Bethmann D; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany., Biehl K; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Wickenhauser C; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany., Seliger B; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.; Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Source: Oncoimmunology [Oncoimmunology] 2022 Apr 28; Vol. 11 (1), pp. 2069214. Date of Electronic Publication: 2022 Apr 28 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35529675
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Subbarayan+K%22">Subbarayan K</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Massa+C%22">Massa C</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Leisz+S%22">Leisz S</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Steven+A%22">Steven A</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Bethmann+D%22">Bethmann D</searchLink>; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Biehl+K%22">Biehl K</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Wickenhauser+C%22">Wickenhauser C</searchLink>; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.<br /><searchLink fieldCode="AU" term="%22Seliger+B%22">Seliger B</searchLink>; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.; Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2022 Apr 28; Vol. 11 (1), pp. 2069214. <i>Date of Electronic Publication: </i>2022 Apr 28 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2162-402X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35529675
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/2162402X.2022.2069214
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2069214
    Titles:
      – TitleFull: Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Subbarayan K
      – PersonEntity:
          Name:
            NameFull: Massa C
      – PersonEntity:
          Name:
            NameFull: Leisz S
      – PersonEntity:
          Name:
            NameFull: Steven A
      – PersonEntity:
          Name:
            NameFull: Bethmann D
      – PersonEntity:
          Name:
            NameFull: Biehl K
      – PersonEntity:
          Name:
            NameFull: Wickenhauser C
      – PersonEntity:
          Name:
            NameFull: Seliger B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2022 Apr 28
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2162-402X
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Oncoimmunology
              Type: main
ResultId 1